Cormorant Asset Management »

Rapport Therapeutics shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2024-12-31 $52M 2.9M 17.74
2024-09-30 $60M 2.9M 20.48
2024-06-30 $68M 2.9M 23.26

More positions owned by Cormorant Asset Management

Moonlake Immunotherapeutics Class A Ord (MLTX)
Praxis Precision Medicines I Com New (PRAX)
Janux Therapeutics (JANX)
Arcellx Common Stock (ACLX)
Edgewise Therapeutics (EWTX)
Newamsterdam Pharma Company Ordinary Shares (NAMS)
Eyepoint Pharmaceuticals Com New (EYPT)
Rapport Therapeutics (RAPP)
Crinetics Pharmaceuticals In (CRNX)
Insmed Com Par $.01 (INSM)
Bridgebio Pharma (BBIO)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Bright Minds Biosciences Com New (DRUG)
Vaxcyte (PCVX)
Merus N V (MRUS)

View all positions for Cormorant Asset Management

Top funds holding Rapport Therapeutics

TRV GP V
FMR
Arch Venture Corp
Cormorant Asset Management
Capital Research and Management Company - Division 3
Johnson & Johnson
Sofinnova Ventures
T. Rowe Price Investment Management
Goldman Sachs Group
T. Rowe Price Associates
Alliancebernstein
Trv Gp Vi
BlackRock
Vanguard Group
Citadel Advisors

View all funds holding Rapport Therapeutics